What is claimed is:

1. A pharmaceutical dosage form comprising an immediate release and an enteric-coated controlled release component,

wherein said immediate release component and said enteric-coated controlled release component each comprises a $GABA_B$ agonist and a pharmaceutically acceptable excipient;

wherein said immediate release component exhibits an *in vitro* dissolution profile comprising at least about 80% $GABA_B$ agonist release after 1 hour;

wherein said enteric-coated controlled release component exhibits an *in vitro* dissolution profile in simulated intestinal fluid medium comprising at least about 40% $GABA_B$ agonist release after 1 hour, and at least about 70% $GABA_B$ agonist release after 4 hours; and

wherein the ratio of said immediate release component to said enteric-coated controlled release component is from about 1:10 to about 10:1.

2. A pharmaceutical dosage form according to claim 1 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:4 to about 4:1.

3. A pharmaceutical dosage form according to claim 1 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:2 to about 1:1.

4. A pharmaceutical dosage form according to claim 1 wherein said $GABA_B$ agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

5. A pharmaceutical dosage form according to claim 4 wherein said baclofen is a racemic mixture.

6. A pharmaceutical dosage form according to claim 4 wherein said baclofen consists essentially of the L-baclofen enantiomer.

7. A pharmaceutical dosage form according to claim 4 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

8. A pharmaceutical dosage form according to claim 4 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

9. A pharmaceutical dosage form according to claim 4 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

10. A pharmaceutical dosage form according to claim 1 wherein said dosage form is a tablet.

11. A pharmaceutical dosage form according to claim 1 wherein said dosage form is a capsule.

12. A pharmaceutical dosage form according to claim 11 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

13. A pharmaceutical dosage form comprising an immediate release and an enteric-coated controlled release component,

wherein said immediate release component and said enteric-coated controlled release component each comprises a $GABA_B$ agonist and a pharmaceutically acceptable excipient;

wherein said immediate release component exhibits an *in vitro* dissolution profile comprising at least about 80% $GABA_B$ agonist release after 1 hour;

wherein said enteric-coated controlled release component exhibits an *in vitro* dissolution profile in simulated gastric fluid/simulated intestinal fluid (2 hour switchover) medium comprising less than about 10% $GABA_B$ agonist release after 2 hours, at least about 40% $GABA_B$ agonist release after 3 hours, and at least about 70% $GABA_B$ agonist release after 6 hours; and

wherein the ratio of said immediate release component to said enteric-coated controlled release component is from about 1:10 to about 10:1.

14. A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:4 to about 4:1.

15. A pharmaceutical dosage form according to claim 13 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:2 to about 1:1.

16. A pharmaceutical dosage form according to claim 13 wherein said $GABA_B$ agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

17. A pharmaceutical dosage form according to claim 16 wherein said baclofen is a racemic mixture.

18. A pharmaceutical dosage form according to claim 16 wherein said baclofen consists essentially of the L-baclofen enantiomer.

19. A pharmaceutical dosage form according to claim 16 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

20. A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

21. A pharmaceutical dosage form according to claim 16 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

22. A pharmaceutical dosage form according to claim 13 wherein said dosage form is a tablet.

23. A pharmaceutical dosage form according to claim 13 wherein said dosage form is a capsule.

24. A pharmaceutical dosage form according to claim 23 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

25. A pharmaceutical dosage form comprising an immediate release and an enteric-coated controlled release component,

wherein said immediate release component and said enteric-coated controlled release component each comprises a $GABA_B$ agonist and a pharmaceutically acceptable excipient; and

wherein said dosage form exhibits an *in vivo* plasma profile comprising mean maximum $GABA_B$ agonist release from about 30 minutes to about 7 hours after administration to a fasting patient.

26. A pharmaceutical dosage form according to claim 25 wherein said *in vivo* plasma profile comprises mean maximum $GABA_B$ agonist release from about 1 hour to about 5.5 hours after administration to a fasting patient.

27. A pharmaceutical dosage form according to claim 25 wherein said *in vivo* plasma profile comprises mean maximum $GABA_B$ agonist release from about 90 minutes to about 5.5 hours after administration to a fasting patient.

28. A pharmaceutical dosage form according to claim 25 wherein said *in vivo* plasma profile comprises mean maximum $GABA_B$ agonist release from about 2 hours to about 5.5 hours after administration to a fasting patient.

29. A pharmaceutical dosage form according to claim 25 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:10 to about 10:1.

30. A pharmaceutical dosage form according to claim 25 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:4 to about 4:1.

31. A pharmaceutical dosage form according to claim 25 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:2 to about 1:1.

32. A pharmaceutical dosage form according to claim 25 wherein said $GABA_B$ agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

33. A pharmaceutical dosage form according to claim 32 wherein said baclofen is a racemic mixture.

34. A pharmaceutical dosage form according to claim 32 wherein said baclofen consists essentially of the L-baclofen enantiomer.

35. A pharmaceutical dosage form according to claim 32 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

36. A pharmaceutical dosage form according to claim 32 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

37. A pharmaceutical dosage form according to claim 32 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

38. A pharmaceutical dosage form according to claim 25 wherein said dosage form is a tablet.

39. A pharmaceutical dosage form according to claim 25 wherein said dosage form is a capsule.

40. A pharmaceutical dosage form according to claim 39 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.

41. A pharmaceutical dosage form comprising an immediate release and an enteric-coated controlled release component,

wherein said immediate release component and said enteric-coated controlled release component each comprises a $GABA_B$ agonist and a pharmaceutically acceptable excipient; and

wherein said dosage form exhibits an *in vivo* plasma profile comprising at least 2 hours of sustained $GABA_B$ agonist concentrations at greater than therapeutic levels, after about 2 hours following administration to a fasting patient.

42. A pharmaceutical dosage form according to claim 41 wherein said dosage form further comprises from about 5% to about 85% $GABA_B$ agonist release in the stomach.

43. A pharmaceutical dosage form according to claim 41 wherein said dosage form further comprises at least about 25% $GABA_B$ agonist release in the intestinal tract.

44. A pharmaceutical dosage form according to claim 41 wherein said dosage form further comprises substantially complete $GABA_B$ agonist release after about 10 hours following administration to a fasting patient.

45. A pharmaceutical dosage form according to claim 41 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:10 to about 10:1.

46. A pharmaceutical dosage form according to claim 41 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:4 to about 4:1.

47. A pharmaceutical dosage form according to claim 41 wherein said ratio of immediate release component to enteric-coated controlled release component is from about 1:2 to about 1:1.

48. A pharmaceutical dosage form according to claim 41 wherein said $GABA_B$ agonist is baclofen, a baclofen prodrug, a baclofen analog, or a mixture thereof.

49. A pharmaceutical dosage form according to claim 48 wherein said baclofen is a racemic mixture.

50. A pharmaceutical dosage form according to claim 48 wherein said baclofen consists essentially of the L-baclofen enantiomer.

51. A pharmaceutical dosage form according to claim 48 wherein said baclofen comprises at least about 95% L-baclofen enantiomer.

52. A pharmaceutical dosage form according to claim 48 wherein said baclofen is in the amount from about 2 mg to about 150 mg.

53. A pharmaceutical dosage form according to claim 48 wherein said baclofen is in the amount from about 2.5 mg to about 100 mg.

54. A pharmaceutical dosage form according to claim 41 wherein said dosage form is a tablet.

55. A pharmaceutical dosage form according to claim 41 wherein said dosage form is a capsule.

56. A pharmaceutical dosage form according to claim 55 wherein said capsule further comprises discrete units selected from the group consisting of beads, granules, particles, or a mixture thereof.